Mizuho Securities USA LLC Raises Stock Position in TLGY Acquisition Co. (NASDAQ:TLGY)

Mizuho Securities USA LLC grew its stake in TLGY Acquisition Co. (NASDAQ:TLGY) by 102.2% in the 3rd quarter, Holdings Channel reports. The firm owned 600,677 shares of the company’s stock after purchasing an additional 303,577 shares during the period. Mizuho Securities USA LLC owned approximately 0.06% of TLGY Acquisition worth $6,728,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Clear Street LLC purchased a new position in shares of TLGY Acquisition during the 2nd quarter worth approximately $62,000. Spartan Fund Management Inc. boosted its position in shares of TLGY Acquisition by 19,927.7% during the third quarter. Spartan Fund Management Inc. now owns 60,083 shares of the company’s stock valued at $693,000 after purchasing an additional 59,783 shares in the last quarter. K2 Principal Fund L.P. bought a new stake in shares of TLGY Acquisition during the 2nd quarter valued at $1,146,000. Wolverine Asset Management LLC boosted its stake in TLGY Acquisition by 0.9% during the third quarter. Wolverine Asset Management LLC now owns 365,828 shares of the company’s stock worth $4,222,000 after acquiring an additional 3,098 shares in the last quarter. Finally, Berkley W R Corp grew its stake in shares of TLGY Acquisition by 71.0% in the 1st quarter. Berkley W R Corp now owns 479,609 shares of the company’s stock worth $5,420,000 after buying an additional 199,139 shares during the last quarter. 45.08% of the stock is owned by hedge funds and other institutional investors.

TLGY Acquisition Price Performance

TLGY stock opened at $11.60 on Friday. The business has a 50 day moving average of $11.55 and a 200 day moving average of $11.49. TLGY Acquisition Co. has a twelve month low of $11.02 and a twelve month high of $11.60.

TLGY Acquisition Profile

TLGY Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. It intends to acquire companies in the biopharma or technology enabled business-to-consumer industries worldwide.